Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

July 6, 2020

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus (HBV) program developed under its 2018 collaboration agreement with Gilead Sciences. Upon the collaboration’s conclusion, effective September 4, 2020, Precision BioSciences will regain full clinical development and commercialization rights to the program.

The Company does not anticipate any changes to its cash runway. As of March 31, 2020, Precision had cash and cash equivalents of $154.2 million, which is expected to sufficiently fund operations into the second half of 2021.

Read more here